Fundz

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

PRIVATEFeb 21, 2024

Position

Chief Medical Officer

Company

Ikena Oncology

Caroline Germa
cgerma@ikenaoncology.com
BostonBiotechnologyHealth CareMedicalTherapeutics

Description

Ikena Oncology, Inc. announces the appointment of Caroline Germa, M.D. as Chief Medical Officer.

Quick answer

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer (February 21, 2024). Ikena Oncology is based in Boston, Massachusetts, United States.

Who is the new Chief Medical Officer at Ikena Oncology?
Ikena Oncology named Caroline Germa Chief Medical Officer, announced February 21, 2024.
What did Ikena Oncology announce on February 21, 2024?
Ikena Oncology, Inc. announces the appointment of Caroline Germa, M.D. as Chief Medical Officer.
What does Ikena Oncology do?
Ikena OncologyTM is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network.
Where is Ikena Oncology based?
Ikena Oncology is based in Boston, Massachusetts, United States.
Which similar companies made leadership changes around the same time?
Hansa Biopharma (February 22, 2024), Diakonos Oncology (February 26, 2024), Compugen (February 15, 2024) and OncoNano Medicine (March 1, 2024) also announced leadership changes within 45 days of Ikena Oncology.

Source: Fundz verified event record.

Other recent leadership changes in Medical and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Ikena Oncology, and when

A new leader at Ikena Oncology brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Ikena Oncology raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ikena Oncology, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ikena Oncology. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Ikena Oncology

Location

Boston, Massachusetts, United States

About

Ikena OncologyTM is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company’s lead targeted oncology program, IK-930, is a TEAD1 selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company’s additional research spans other targets in the Hippo pathway as well as the RAS signaling pathway, including developing IK-595, a novel MEK-RAF inhibitor. Additionally, IK-175, an AHR antagonist, is being developed in collaboration with Bristol Myers Squibb. Ikena aims to utilize their depth of institutional knowledge and breadth of tools to efficiently develop the right drug using the right modality for the right patient. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Ikena Oncology changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Caroline
Likely contact at this company
••••••••@••••••••

See Caroline's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Ikena Oncology's next move

Learn about Strategic plan

Ikena Oncology changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.